Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Stardust Power stock logo

1. Stardust Power NASDAQ:SDST

$0.69 -0.02 (-2.70%)
As of 01:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Market Capitalization
$36.21 million
Consensus Rating
Buy
Consensus Price Target
$7.94 (+1,057.1% Upside)
Volume
101,163 shares
Average Volume
1.11 million shares
Today's Range
$0.67
$0.70
Context Therapeutics stock logo

2. Context Therapeutics NASDAQ:CNTX

$0.82 -0.01 (-0.68%)
As of 01:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$61.50 million
P/E Ratio
-0.90
Consensus Rating
Buy
Consensus Price Target
$6.33 (+672.4% Upside)
Volume
23,099 shares
Average Volume
387,414 shares
Clearside Biomedical stock logo

3. Clearside Biomedical NASDAQ:CLSD

$0.83 +0.04 (+5.24%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More about Clearside Biomedical

Market Capitalization
$62.95 million
P/E Ratio
-1.84
Consensus Rating
Buy
Consensus Price Target
$5.33 (+542.6% Upside)
Volume
248,897 shares
Average Volume
395,622 shares
Century Therapeutics stock logo

4. Century Therapeutics NASDAQ:IPSC

$0.64 +0.03 (+4.58%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century Therapeutics

Market Capitalization
$54.76 million
P/E Ratio
-0.35
Consensus Rating
Buy
Consensus Price Target
$10.00 (+1,452.8% Upside)
Volume
416,022 shares
Average Volume
495,637 shares
Vor Biopharma stock logo

5. Vor Biopharma NYSE:VOR

$0.88 -0.07 (-7.67%)
As of 01:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. More about Vor Biopharma

Market Capitalization
$60.36 million
P/E Ratio
-0.53
Consensus Rating
Buy
Consensus Price Target
$11.36 (+1,192.1% Upside)
Volume
382,001 shares
Average Volume
611,878 shares
Elevation Oncology stock logo

6. Elevation Oncology NASDAQ:ELEV

$0.48 +0.00 (+0.84%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. More about Elevation Oncology

Market Capitalization
$28.38 million
P/E Ratio
-0.59
Consensus Rating
Buy
Consensus Price Target
$7.20 (+1,400.0% Upside)
Volume
949,999 shares
Average Volume
1.25 million shares
Ovid Therapeutics stock logo

7. Ovid Therapeutics NASDAQ:OVID

$0.52 +0.03 (+5.41%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$36.93 million
P/E Ratio
-1.11
Consensus Rating
Buy
Consensus Price Target
$4.03 (+675.6% Upside)
Volume
90,397 shares
Average Volume
416,694 shares
Biodesix stock logo

8. Biodesix NASDAQ:BDSX

$0.77 +0.06 (+7.99%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. More about Biodesix

Market Capitalization
$112.01 million
P/E Ratio
-1.97
Consensus Rating
Buy
Consensus Price Target
$2.95 (+283.1% Upside)
Volume
4.74 million shares
Average Volume
491,693 shares
Cognition Therapeutics stock logo

9. Cognition Therapeutics NASDAQ:CGTX

$0.42 -0.02 (-3.58%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More about Cognition Therapeutics

Market Capitalization
$17.24 million
P/E Ratio
-0.43
Consensus Rating
Buy
Consensus Price Target
$8.30 (+1,904.8% Upside)
Volume
1.23 million shares
Average Volume
2.06 million shares
Tenaya Therapeutics stock logo

10. Tenaya Therapeutics NASDAQ:TNYA

$0.46 -0.48 (-51.00%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization
$37.31 million
P/E Ratio
-0.33
Consensus Rating
Buy
Consensus Price Target
$17.33 (+3,635.6% Upside)
Volume
14.92 million shares
Average Volume
1.75 million shares
Beyond Air stock logo

11. Beyond Air NASDAQ:XAIR

$0.27 +0.01 (+3.09%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. More about Beyond Air

Market Capitalization
$18.30 million
P/E Ratio
-0.25
Consensus Rating
Buy
Consensus Price Target
$3.67 (+1,278.4% Upside)
Volume
974,833 shares
Average Volume
1.49 million shares
Nektar Therapeutics stock logo

12. Nektar Therapeutics NASDAQ:NKTR

$0.85 +0.05 (+6.25%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. More about Nektar Therapeutics

Market Capitalization
$156.79 million
P/E Ratio
-1.01
Consensus Rating
Moderate Buy
Consensus Price Target
$4.08 (+379.3% Upside)
Volume
1.01 million shares
Average Volume
1.96 million shares
Mersana Therapeutics stock logo

13. Mersana Therapeutics NASDAQ:MRSN

$0.52 +0.04 (+8.13%)
As of 01:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More about Mersana Therapeutics

Market Capitalization
$64.11 million
P/E Ratio
-0.85
Consensus Rating
Moderate Buy
Consensus Price Target
$4.25 (+718.9% Upside)
Volume
3.96 million shares
Average Volume
7.10 million shares
Rallybio stock logo

14. Rallybio NASDAQ:RLYB

$0.70 +0.01 (+1.59%)
As of 01:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More about Rallybio

Market Capitalization
$29.13 million
P/E Ratio
-0.44
Consensus Rating
Moderate Buy
Consensus Price Target
$9.75 (+1,288.9% Upside)
Volume
27,222 shares
Average Volume
62,833 shares
Omega Therapeutics stock logo

15. Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)
Closing price 02/24/2025
Extended Trading
$0.12 0.00 (0.00%)
As of 02/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. More about Omega Therapeutics

Market Capitalization
$6.92 million
P/E Ratio
-0.09
Consensus Rating
Moderate Buy
Consensus Price Target
$9.20 (+7,260.0% Upside)
Volume
4.81 million shares
Average Volume
15.22 million shares
Affimed stock logo

16. Affimed NASDAQ:AFMD

$0.96 -0.04 (-4.06%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. More about Affimed

Market Capitalization
$15.46 million
Consensus Rating
Moderate Buy
Consensus Price Target
$13.50 (+1,310.7% Upside)
Volume
65,801 shares
Average Volume
306,269 shares
Today's Range
$0.95
$1.00
Cresco Labs stock logo

17. Cresco Labs OTCMKTS:CRLBF

$0.82 -0.06 (-6.98%)
As of 03/3/2025 03:59 PM Eastern

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco Labs

Market Capitalization
$400.28 million
P/E Ratio
-4.10
Consensus Rating
Moderate Buy
Consensus Price Target
$2.50 (+204.9% Upside)
Volume
3.52 million shares
Average Volume
605,376 shares
Wag! Group stock logo

18. Wag! Group NASDAQ:PET

$0.24 -0.02 (-5.84%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Wag! Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. More about Wag! Group

Market Capitalization
$12.05 million
P/E Ratio
-0.62
Consensus Rating
Moderate Buy
Consensus Price Target
$4.90 (+1,924.8% Upside)
Volume
331,242 shares
Average Volume
715,814 shares
Sangamo Therapeutics stock logo

19. Sangamo Therapeutics NASDAQ:SGMO

$0.89 -0.03 (-3.53%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More about Sangamo Therapeutics

Market Capitalization
$184.44 million
P/E Ratio
-1.18
Consensus Rating
Moderate Buy
Consensus Price Target
$5.17 (+481.8% Upside)
Volume
2.74 million shares
Average Volume
4.76 million shares
Adicet Bio stock logo

20. Adicet Bio NASDAQ:ACET

$0.87 +0.03 (+3.00%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$71.85 million
P/E Ratio
-0.51
Consensus Rating
Moderate Buy
Consensus Price Target
$7.50 (+759.1% Upside)
Volume
302,256 shares
Average Volume
1.02 million shares
Viracta Therapeutics stock logo

21. Viracta Therapeutics NASDAQ:VIRX

$0.02 0.00 (-10.67%)
As of 01:15 PM Eastern

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. More about Viracta Therapeutics

Market Capitalization
$799 thousand
P/E Ratio
-0.02
Consensus Rating
Moderate Buy
Consensus Price Target
$4.05 (+20,049.3% Upside)
Volume
46,272 shares
Average Volume
1.07 million shares
Innoviz Technologies stock logo

22. Innoviz Technologies NASDAQ:INVZ

$0.73 +0.04 (+5.48%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innoviz Technologies Ltd. manufactures and sells automotive grade LiDAR sensors and perception software to enable safe autonomous driving at a mass scale. More about Innoviz Technologies

Market Capitalization
$99.69 million
P/E Ratio
-1.14
Consensus Rating
Moderate Buy
Consensus Price Target
$3.19 (+336.3% Upside)
Volume
2.99 million shares
Average Volume
14.00 million shares
CytomX Therapeutics stock logo

23. CytomX Therapeutics NASDAQ:CTMX

$0.64 -0.01 (-1.43%)
As of 01:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More about CytomX Therapeutics

Market Capitalization
$50.16 million
P/E Ratio
3.77
Consensus Rating
Moderate Buy
Consensus Price Target
$5.77 (+800.5% Upside)
Volume
243,610 shares
Average Volume
2.41 million shares
Applied Therapeutics stock logo

24. Applied Therapeutics NASDAQ:APLT

$0.47 +0.01 (+2.44%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More about Applied Therapeutics

Market Capitalization
$54.92 million
P/E Ratio
-0.29
Consensus Rating
Moderate Buy
Consensus Price Target
$6.10 (+1,197.9% Upside)
Volume
1.41 million shares
Average Volume
4.43 million shares
i-80 Gold stock logo

25. i-80 Gold NYSE:IAUX

$0.75 -0.02 (-2.96%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. More about i-80 Gold

Market Capitalization
$327.99 million
P/E Ratio
-2.07
Consensus Rating
Moderate Buy
Consensus Price Target
$3.50 (+368.5% Upside)
Volume
1.41 million shares
Average Volume
5.50 million shares